Loading clinical trials...

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGPHASE2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

NCT04856085•Vir Biotechnology, Inc.

View on ClinicalTrials.gov

Summary

This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female ages 18 - \<66 years
•Chronic HBV infection for \>/= 6 months
•On NRTI therapy for \>/= 2 months at the time of screening

Exclusion Criteria

•Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation
•Significant fibrosis or cirrhosis
•History or evidence of drug or alcohol abuse
•History of chronic liver disease from any cause other than chronic HBV infection
•History of hepatic decompensation
•History of anaphylaxis
•History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434
•History of immune complex disease
•History of known contraindication to any interferon product

Locations (37)

Investigative Site

San Francisco, California, United States

Investigative Site

Miami, Florida, United States

Investigative Site

Orlando, Florida, United States

Investigative Site

Baltimore, Maryland, United States

Investigative Site

Hillsborough, New Jersey, United States

Investigative Site

Toronto, Canada

Investigative Site

Toronto, Canada

Investigative Site

Vancouver, Canada

Investigative Site

Frankfurt, Germany

Investigative Site

Hanover, Germany

Key Dates

Start Date

July 11, 2021

Primary Completion Date

March 1, 2026

Completion Date

March 1, 2026

Last Updated

October 21, 2025

Enrollment

244

ACTUAL participants

Conditions

Hepatitis B, Chronic

Interventions

VIR-2218

DRUG

VIR-3434

DRUG

PEG-IFNα

DRUG

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

NCT04166266

Hepatitis D, ChronicHepatitis B, Chronic

View study

RECRUITING

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

NCT06550622

Hepatitis B, Chronic

View study

RECRUITINGEARLY_PHASE1

Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Inclusion Criteria

Exclusion Criteria

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B

Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Effectiveness of Antiviral Treatment in Cirrhotic Patients with Low-level Hepatitis B Virus DNA Levels

Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)